Clinical Trial Update: Cardioprotective Effects of GLP-1 and Their Mechanisms [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating whether glucagon-like peptide-1 (GLP-1) has cardioprotective effects and exploring its mechanisms in patients with angina pectoris.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angina Pectoris

Drugs mentioned

• GLP-1 (glucagon-like peptide-1)

Snippet

Sponsor: Papworth Hospital NHS Foundation Trust | Conditions: Angina Pectoris | Phase 1 | Status: COMPLETED